Feedback
Settings

Settings

Goto Application

83,864 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(NYHBQMYGNKIUIF-UUOKFMHZSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 8,387
1.WO/2026/014994MUTANT STRAIN OF ESCHERICHIA COLI OR STAPHYLOCOCCUS AUREUS DERIVED FROM BOVINE MASTITIS AND VACCINE COMPOSITION CONTAINING SAME
WO - 15.01.2026
Int.Class A61K 39/108
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
108Escherichia; Klebsiella
 Appl.No PCT/KR2025/010307 Applicant THE YOON HEALTHTECH CO.,LTD. Inventor YOON, Jang Won
The present invention relates to a mutant strain of Escherichia coli or Staphylococcus aureus derived from bovine mastitis and a vaccine composition containing same. The vaccine composition according to the present invention may be usefully employed to reduce economic losses caused by bovine mastitis and to improve productivity and sustainability across the dairy industry.
2.WO/2026/015864CD8 BINDING POLYPEPTIDES AND METHODS OF USE
WO - 15.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/037399 Applicant OUTPACE BIO, INC. Inventor BAKER, Laura
The present disclosure relates to novel CD8 binding polypeptides, conjugates thereof, and methods of use thereof.
3.WO/2026/0143655’ CAP ANALOG
WO - 15.01.2026
Int.Class C07H 19/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
20with the saccharide radical being esterified by phosphoric or polyphosphoric acids
 Appl.No PCT/JP2025/024109 Applicant NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM Inventor ABE, Hiroshi
Provided is a technique for more easily obtaining a 5’ capped polynucleotide which is purified and exhibits high translation activity. The 5' cap analog is characterized in that a hydroxy group at the 2’ and/or 3’ position of ribose contained in 7-methylguanylic acid is substituted with a non-photodegradable hydrophobic protecting group.
4.WO/2026/013624DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
WO - 15.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/IB2025/057021 Applicant NOVARTIS AG Inventor HUNZIKER, Juerg
Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), for example, human HMGCR, compositions including the same, and methods of treatment using the same.
5.WO/2026/015080LINKAGE GROUPS, OLIGONUCLEOTIDE CONJUGATES, AND METHODS THEREOF
WO - 15.01.2026
Int.Class C07H 9/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
9Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
02the hetero ring containing only oxygen as ring hetero atoms
04Cyclic acetals
 Appl.No PCT/SG2025/050460 Applicant AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH Inventor YING, Jackie Yi-ru
This disclosure concerns linkage groups and uses thereof for conjugating ligands to nucleic acids. Also provided are oligonucleotide-ligand conjugates containing the linkage group, and uses thereof for targeted nucleic acid delivery and as a medicament.
6.WO/2026/013176ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
WO - 15.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/069685 Applicant PROQR THERAPEUTICS II B.V. Inventor HOLKERS, Maarten
The disclosure relates to the field of diseases caused by high levels of LDL-C and/or fibrinogen, such as cardiovascular disease (CVD). The disclosure involves antisense oligonucleotides (AONs) for RNA editing technology in deaminating a specific adenosine in transcript molecules of the human Asparagine-Linked Glycosylation 12 homolog glycosyltransferase (ALG12) gene, thereby rendering a mutation from a serine residue at position 275 in the human ALG12 amino acid sequence to a glycine residue (S275G).
7.WO/2026/014451INDUCER FOR PROTEIN PRODUCTION
WO - 15.01.2026
Int.Class C12P 1/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
1Preparation of compounds or compositions, not provided for in groups C12P3/-C12P39/121; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
02by using fungi
 Appl.No PCT/JP2025/024576 Applicant TORAY INDUSTRIES, INC. Inventor KAGAWA Yusuke
Plant fibers derived from blended fibers containing plant fibers and fibers other than plant fibers have excellent protein induction ability in protein production by filamentous fungus culture and thus can be used suitably as an inducer for enhancing the productivity of protein production by filamentous fungus culture.
8.WO/2026/015876IMPROVED METHODS FOR IN VITRO TRANSCRIPTION
WO - 15.01.2026
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No PCT/US2025/037414 Applicant ARCTURUS THERAPEUTICS, INC. Inventor HILL, Brett Dallas
Disclosed herein are methods of producing transcribed RNA product with increased yield and reduced RNA degradation.
9.WO/2026/015607METHODS FOR PARTITIONING HYPER-, HYPO-, AND NON-METHYLATED DNA
WO - 15.01.2026
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
 Appl.No PCT/US2025/036932 Applicant GUARDANT HEALTH, INC. Inventor KENNEDY, Andrew
Provided herein are methods of processing DNA of a sample. The methods can comprise steps of (a) partitioning the DNA into a plurality of subsamples by contacting the DNA with an agent that recognizes methyl cytosine in the DNA, (b) contacting the DNA of the sample or a subsample thereof with a methyltransferase in the presence of an azide donor or an amine donor, thereby labeling unmethylated CpGs in the DNA with azide or an amine and providing azide-labeled DNA or amine-labeled DNA, respectively, and (c) tagging the azide-labeled DNA or the amine-labeled DNA, and separating the tagged, azide-labeled DNA from DNA of the second subsample that is not azide-labeled or separating the tagged, amine-labeled DNA from DNA of the second subsample that is not amine-labeled. In some embodiments of the disclosed methods, these steps are performed in a different order.
10.WO/2026/015202CELL-FREE IN VITRO METHODS FOR CHARACTERIZATION OF BASE EDITOR PROPERTIES AND DETERMINATION OF BASE EDITOR EDITING OUTCOMES
WO - 15.01.2026
Int.Class C12Q 1/6827
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6827for detection of mutation or polymorphism
 Appl.No PCT/US2025/029391 Applicant SIGMA-ALDRICH CO. LLC Inventor BRETTMANN, Erin
The present invention is directed toward methods for the in vitro characterization of base editor proteins and the in vitro determination of base editor outcomes at a target site.
# -